Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER

Therapy resistance beyond cellular dormancy

It is commonly accepted that disseminated tumour cells survive cytotoxic chemotherapy because they are not proliferating. A new study now finds that, in contrast to this long-standing concept, both dormant and proliferative cancer cells can be protected from chemotherapy when they reside at the perivascular niche.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Mechanisms of therapy resistance in manifest metastasis versus early systemic cancer.

References

  1. Shapiro, C. L. & Recht, A. New Engl. J. Med. 344, 1997–2008 (2001).

    Article  CAS  Google Scholar 

  2. Early Breast Cancer Trialists’ Collaborative, G. Lancet Oncol. 19, 27–39 (2018).

    Article  Google Scholar 

  3. Pantel, K. et al. J. Natl Cancer Inst. 85, 1419–1424 (1993).

    Article  CAS  Google Scholar 

  4. Braun, S. et al. J. Clin. Oncol. 18, 80–86 (2000).

    Article  CAS  Google Scholar 

  5. Carlson, P. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-018-0267-0 (2019).

    Article  PubMed  Google Scholar 

  6. Werner-Klein, M. et al. Nat. Commun. 9, 595 (2018).

    Article  Google Scholar 

  7. Hosseini, H. et al. Nature 540, 552–558 (2016).

    Article  CAS  Google Scholar 

  8. Spencer, J. A. et al. Nature 508, 269–273 (2014).

    Article  CAS  Google Scholar 

  9. Fluegen, G. et al. Nat. Cell Biol. 19, 120–132 (2017).

    Article  CAS  Google Scholar 

  10. Sosa, M. S. et al. Nat. Commun. 6, 6170 (2015).

    Article  CAS  Google Scholar 

  11. Joyce, J. A. & Pollard, J. W. Nat. Rev. Cancer 9, 239–252 (2009).

    Article  CAS  Google Scholar 

  12. Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Nat. Rev. Cancer 13, 714–726 (2013).

    Article  CAS  Google Scholar 

  13. Minchinton, A. I. & Tannock, I. F. Nat. Rev. Cancer 6, 583–592 (2006).

    Article  CAS  Google Scholar 

  14. Croucher, P. I., McDonald, M. M. & Martin, T. J. Nat. Rev. Cancer 16, 373–386 (2016).

    Article  CAS  Google Scholar 

  15. Chuang, H. N. et al. Glia 61, 1331–1346 (2013).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christoph A. Klein.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Werner-Klein, M., Klein, C.A. Therapy resistance beyond cellular dormancy. Nat Cell Biol 21, 117–119 (2019). https://doi.org/10.1038/s41556-019-0276-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41556-019-0276-7

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer